Providing information about health culture, prevention of socially significant diseases, providing care for disadvantaged people, public engagement of employees – these are our priorities in the work for the benefit of society. The social and health care for the elderly– this is not only medical treatment but care and attention as well. The endless waiting and queues in front of the GP’s cabinet, sometimes only to measure the blood pressure, is hard for a pensioner.

The Chairman of the Board of Directors of Sopharma Ognian Donev was elected Vice-President of the Vienna Economic Forum. Thus, he will be one of the three Vice-Presidents of the President of the Organisation Mr. Erhard Busek who was Vice-Chancellor of Austria in the period of 1991-1995 and Special Co-ordinator of the Stability Pact for South-Eastern Europe in the period of 2002-2008. The Vienna Economic Forum is an organisation making its object to promote and help for the practical achievement of investments in the region from the Adriatic to the Black Sea.

"Cytisine has been available in the former socialist economy countries of eastern Europe since 1964. Made by the Bulgarian drug company Sopharma AD and sold as Tabex, it has never been available to most of the rest of the world. A new study from New Zealand reported in the Dec. 18 New England Journal of Medicine compared the cessation results of cytisine to varenicline." http://www.winonadailynews.com Tobacco is likely the most addictive chemical we humans encounter (except maybe for Oreo cookies.

Current report No. 15/2015 dated 5 February 2015 NOTIFICATION Sopharma AD notifies that for January 2015 the Company recorded a decrease of sales revenues of 43% compared to the same month of 2014, including 11% increase of domestic sales and 61% decrease of export sales. The volatility of the RUB caused us to undertake actions to adjust the prices for our main export market - Russia, which prevented us from exporting during the period. Our forecast is that this slow down in the beginning of the year will be compensated already in the first quarter.

ACQUISITION OF OWN SHARES Current report No 14/2015 Dated 5 February 2015 SOPHARMA AD hereby informs that from 29 January 2015 up to and including 4 February 2015 the Company bought 3 200 own shares representing 0.0024% of the share capital of the Company, at a total value of 11 534.90 BGN on the Bulgarian Stock Exchange, the average price per share was 3.605 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.